Royal London Asset Management
UTHR icon

Royal London Asset Management’s United Therapeutics UTHR Stock Holding History

Royal London Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$910K Hold
1,679
– – ﹤0.01% 617
2026
Q1 		$996K Hold
1,679
– – ﹤0.01% 612
2025
Q4 		$818K Buy
1,679
+411
+32% +$191K ﹤0.01% 626
2025
Q3 		$532K Hold
1,268
– – ﹤0.01% 643
2025
Q2 		$364K Sell
1,268
-742
-37% -$222K ﹤0.01% 692
2025
Q1 		$620K Buy
+2,010
New +$689K ﹤0.01% 664

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Royal London Asset Management's UTHR Position: Q2 2026 in Review

Royal London Asset Management held its United Therapeutics (UTHR) position steady in Q2 2026 at 1,679 shares worth $910K. The position accounts for ﹤0.01% of the portfolio, ranked #617.

Royal London Asset Management first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. The position peaked at $996K in Q1 2026. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Royal London Asset Management held 1,679 shares of United Therapeutics worth $910K as of Q2 2026.
  • Royal London Asset Management left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Royal London Asset Management's portfolio in Q2 2026, its #617 holding.
  • Royal London Asset Management first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Royal London Asset Management's United Therapeutics position peaked at $996K in Q1 2026.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.